{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:25:35Z","timestamp":1770481535508,"version":"3.49.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2001,2]]},"abstract":"<jats:p>\n            <jats:italic>Background and Purpose<\/jats:italic>\n            \u2014The purpose of this study was to investigate the effect of the angiotensin-converting enzyme inhibitor perindopril on mean arterial blood pressure (MABP), cerebral blood flow (CBF), and glomerular filtration rate in hypertensive stroke patients with moderate to severe internal carotid artery (ICA) disease or ICA occlusion.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Methods<\/jats:italic>\n            \u2014Twenty-four nonacute ischemic stroke patients who had MABP readings &gt;100 mm Hg and moderate to severe ICA stenosis or occlusion were randomized to receive perindopril 4 mg daily or placebo for 14 days. MABP, ICA flow, and both middle cerebral artery (MCA) velocity and resistance index were measured before dose, at 5 time points over the subsequent 24 hours, and finally at 2 weeks. Brain hexamethyl propylene amine oxide single photon emission computed tomography scans were performed before drug administration and at time of peak drug effect (6 to 8 hours) after the first dose. Glomerular filtration rate was measured with\n            <jats:sup>51<\/jats:sup>\n            Cr EDTA before medication and at 14 days.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Results<\/jats:italic>\n            \u2014A placebo-corrected BP fall of 17\/10 mm Hg was seen (\n            <jats:italic>P<\/jats:italic>\n            =0.017), which was maximal at 5.5 hours. No significant change in ICA flow or MCA velocity was seen between groups. No significant change in hemispheric CBF was seen. The mean change from baseline in the treated group was \u22120.79 mL \u00b7 100 g\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 min\n            <jats:sup>\u22121<\/jats:sup>\n            (95% confidence interval [CI], 1.65 to \u22123.23); mean change in the placebo group was \u22121.9 mL \u00b7 100 g\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 min\n            <jats:sup>\u22121<\/jats:sup>\n            (95%CI, 3.02 to \u22126.92). Peri-infarct CBF was similarly unaffected. One of the treated patients developed transient acute renal impairment and was withdrawn from the study on day 4.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Conclusions<\/jats:italic>\n            \u2014Perindopril lowers BP without lowering CBF in hypertensive stroke patients with moderate to severe ICA stenosis or occlusion; monitoring of this patient population for the complications of renal artery stenosis should be considered.\n          <\/jats:p>","DOI":"10.1161\/01.str.32.2.473","type":"journal-article","created":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T20:10:52Z","timestamp":1308341452000},"page":"473-478","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Effect of Perindopril on Cerebral and Renal Perfusion in Stroke Patients With Carotid Disease"],"prefix":"10.1161","volume":"32","author":[{"given":"M. R.","family":"Walters","sequence":"first","affiliation":[{"name":"From the University Department of Medicine and Therapeutics (M.R.W., A.G.D., K.R.L.) and Department of Nuclear Medicine (A.B.), University of Glasgow, Glasgow, Scotland, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bolster","sequence":"additional","affiliation":[{"name":"From the University Department of Medicine and Therapeutics (M.R.W., A.G.D., K.R.L.) and Department of Nuclear Medicine (A.B.), University of Glasgow, Glasgow, Scotland, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G.","family":"Dyker","sequence":"additional","affiliation":[{"name":"From the University Department of Medicine and Therapeutics (M.R.W., A.G.D., K.R.L.) and Department of Nuclear Medicine (A.B.), University of Glasgow, Glasgow, Scotland, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. R.","family":"Lees","sequence":"additional","affiliation":[{"name":"From the University Department of Medicine and Therapeutics (M.R.W., A.G.D., K.R.L.) and Department of Nuclear Medicine (A.B.), University of Glasgow, Glasgow, Scotland, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","first-page":"827","volume":"355","year":"1990","unstructured":"Collins R, Peto R, McMahon S. Blood pressure, stroke and coronary heart disease, 2: overview of randomised drug trials in their epidemiological context. Lancet. 1990;355:827\u2013838.","journal-title":"Lancet"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.66.3.206"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1985.04060090081018"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000108483"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000108016"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198911000-00008"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.28.3.580"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1998.tb07291.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0741-5214(93)90019-I"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Brott T Adams HP Olinger CP Marler JR. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20;864\u2013870.","DOI":"10.1161\/01.STR.20.7.864"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199505000-00004"},{"key":"e_1_3_2_12_2","first-page":"195","volume":"19","year":"1992","unstructured":"Matsuda H, Tsuji N, Sumyima H. A quantitative approach to technetium-99m hexamethyl propylene amine oxide SPECT. Eur J Nucl Med. 1992;19:195\u2013200.","journal-title":"Eur J Nucl Med"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Matsuda H Tsuji N Shuke N. Non-invasive measurement of regional cerebral blood flow. Eur J Nucl Med 1993;20;391\u2013401.","DOI":"10.1007\/BF00208997"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01728304"},{"key":"e_1_3_2_15_2","first-page":"8703","volume":"3","year":"1992","unstructured":"Stromberg C, Naveri L, Saavedra JM. Angiotensin AT2 receptors regulate cerebral blood flow in rats. Neuroreport. 1992;3:8703\u20138704.","journal-title":"Neuroreport"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199309000-00005"},{"key":"e_1_3_2_17_2","first-page":"551","volume":"9","year":"1987","unstructured":"Minenematsu K, Yamaguchi T, Tsuchiya M, Ito K, Ikeda M, Omae T. Effect of the angiotensin converting enzyme inhibitor captopril on cerebral blood flow in hypertensive patients without a history of stroke. Clin Exp Hypertens. 1987;9:551\u2013557.","journal-title":"Clin Exp Hypertens"},{"key":"e_1_3_2_18_2","first-page":"67","volume":"17","year":"1997","unstructured":"Textor SC. Renal failure related to angiotensin converting enzyme inhibitors. Semin Nephrol. 1997;17:67\u201376.","journal-title":"Semin Nephrol"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7178.257"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90262-C"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/5.1.8"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.7.761"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.STR.32.2.473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T22:32:13Z","timestamp":1715553133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.STR.32.2.473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["10.1161\/01.STR.32.2.473"],"URL":"https:\/\/doi.org\/10.1161\/01.str.32.2.473","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2]]},"assertion":[{"value":"2000-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-11-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}